Sales & Marketing News | pharmaphorum

News

Trulicity helps SGLT-2 patients lower blood sugar

New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.

News

Eisai disappointed after NICE rejects earlier use for breast...

NICE says no to Halaven in second line breast cancer

News

Illustration of a nerve cell on a colored background with light effects

FDA advisers reject new use for Pacira nerve block

Doubts over nerve blocker Exparel

News

Hep C woes to continue - but Gilead willing to acquire again

Gilead recorded a loss of $3.9 billion in Q4 because of a one-off charge linked to US tax reforms – however it has bigger problems because of the decline in its hepatitis C portfolio.<

News